Lilly has 11 obesity drugs in its pipeline and wants to develop more treatments for Alzheimer’s disease, ALS and other brain diseases, CEO David Ricks said.
Recent Posts
- Elon Musk reveals SEC sent him ‘settlement demand’ after Twitter buyout probe
- Flushing Financial seeks to raise $70 million to shore up capital as it unloads underwater bonds
- Broadcom shares rise 11%, company says AI revenue more than tripled this year
- Dow tumbles 200 points, Nasdaq retreats back below 20,000 after warm inflation report: Live updates
- Egg prices may soon ‘flirt with record highs,’ supplier says. Here’s why